17 research outputs found

    Predicted HRV-QPM pentamers compared to representative major (HRV-14) and minor (HRV-2) group HRV pentamers derived from crystallography data.

    No full text
    <p>(A) HRV-QPM versus HRV-14 SimPlot data projected onto a space filling depiction of the predicted HRV-QPM pentamer. Shading represents the amino acid identity (26–69%). The yellow dashed triangle represents a single icosahedral asymmetric unit (Tβ€Š=β€Šp3 conformation) composed of VP1 and VP2 from the same protomer and VP3 for an adjacent protomer. The major group domains of interest are divided between two asymmetric units for ease of viewing. Receptor (white) and antigenic (red) sites are shown in outline. (B) Top view ribbon depiction of a major group HRV pentamer (HRV-14; gray) with labelled antigenic neutralisation sites (NImIA-III, green) and combined HRV A (HRV-16) and B (HRV-14)ICAM-1 receptor footprints (red) <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0001847#pone.0001847-Laine1" target="_blank">[6]</a>, <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0001847#pone.0001847-Lole1" target="_blank">[37]</a>. Magnified areas of interest (boxed) highlight computer-based predictive comparisons to the equivalent HRV-QPM (orange) structures of interest. Arrows indicate structures and corresponding sequences of interest (refer to text). (C) HRV-QPM versus HRV-2 SimPlot data projected onto the HRV-QPM pentamer. The domains of interest are mostly shown within a single asymmetric unit. (D) A minor group pentamer (HRV-2; gray) including antigenic sites (sites A–C, green) and VLDL-R footprint (red) <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0001847#pone.0001847-Hofer1" target="_blank">[10]</a>. Attachment of the VLDL-R involves adjacent VP1 molecules. Magnified VP1 area represents one half of a VLDL-R footprint <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0001847#pone.0001847-Stanway1" target="_blank">[42]</a>. Amino acid substitutions (arrowed) contributed to the differences between minor group sites B and C.</p

    Demographic and clinical characteristics of 96 patients randomized to treatment of Azithromycin (nβ€Š=β€Š50) or placebo (nβ€Š=β€Š46) and by ethnicity.

    No full text
    <p><b>Median and IQR (25–75) for continuous variables. Actual numbers for categorical variables and percentages.</b></p><p><b>NB</b>: Missing variables described.</p><p><b>Azithromycin</b>: Gestational age β€Š=β€Š3 (6%). Birth weight β€Š=β€Š6 (12%). Mother smoked during pregnancy β€Š=β€Š3 (6%). Exposure to household smoke β€Š=β€Š2 (4%), <b>Placebo</b>: Gestational age: β€Š=β€Š2 (4%). Birth weight β€Š=β€Š3 (6.5%).</p><p><b>Indigenous children</b>: Gestational age β€Š=β€Š2 (3.3%). Birth weight β€Š=β€Š4 (6.5%). Mother smoked during pregnancy β€Š=β€Š2 (3%). Exposure to household smoke β€Š=β€Š1 (1.6%): <b>Non Indigenous children</b>: Gestational age: β€Š=β€Š3 (8.6%). Birth weight β€Š=β€Š5 (14.3%) Mother smoked during pregnancy β€Š=β€Š1 (3%). Exposure to household smoke β€Š=β€Š1 (3%).</p

    HRV-QPM detections and association of co-morbidities and severity of respiratory illness upon discharge.

    No full text
    <p>HMPV-Human metapneumovirus, HCoV-229E or -NL63-Human coronaviruses, HBoV-Human bocavirus, WUPyV-WU polyomavirus. Labs-Myco/Pert- laboratory testing for <i>Mycoplasma spp.</i> or <i>Bordetella pertussis.</i><sup>1</sup>Steroids, <sup>2</sup>adrenalin or <sup>3</sup>bronchodilators administered, <sup>4</sup>Comparison of severity score using Wilcoxon rank-sum test for HRV-QPM cases with and without co-detection, pβ€Š=β€Š0.88. <sup>5</sup>Recorded as β€˜zero’ due to the patient being admitted for cardiac surgery and all criteria were in relation to the surgery and not the ARTI. <sup>*</sup> Not admitted. CF-cystic fibrosis. NC-No chart could be obtained for review, CHD-congenital heart disease. NN-No notes were available from presentation during the preliminary study.</p

    Comparison of HRV-QPM and HEV structures at the sites comprising HEV receptor footprints.

    No full text
    <p>Figures indicate comparison of the predicted structures of HRV-QPM (orange) with representative HEVs (gray) in regions identified as HEV receptor footprints (red) across VP1, VP2 and VP3 proteins. RMSD values shown for conformational comparison of CAR and HRV-QPM structures, in angstroms.</p

    Adherence of the newly identified HRV A2s to the ICTV species demarcation criteria.

    No full text
    <p>Numbers next to species indicates the number of polyprotein sequences included in the comparison. Bracketed percentages indicate G+C content variation of the HRV A2 polyprotein coding region to reference species. TD-to be determined. <sup>*</sup> See <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0001847#pone-0001847-g006" target="_blank">Figure 6</a> for accession numbers.</p

    Criteria used to determine the severity[60] of respiratory illness upon discharge, in patients presenting to Queensland hospitals who tested positive for HRV-QPM.

    No full text
    1<p>Respiratory support by oxygen therapy and/or mechanical ventilation, <sup>2</sup>Supplementary fluids delivered by either intravenous and/or nasogastric route, <sup>3</sup><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0001847#pone.0001847-Wainwright1" target="_blank">[61]</a>.</p
    corecore